GSK plc
GSK · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $55,091 | $59,038 | $58,477 | $52,172 |
| - Cash | $3,693 | $3,743 | $3,723 | $5,789 |
| + Debt | $16,986 | $22,969 | $20,987 | $32,741 |
| Enterprise Value | $68,384 | $78,265 | $75,741 | $79,124 |
| Revenue | $31,376 | $30,328 | $29,324 | $24,696 |
| % Growth | 3.5% | 3.4% | 18.7% | – |
| Gross Profit | $22,328 | $21,763 | $19,770 | $16,533 |
| % Margin | 71.2% | 71.8% | 67.4% | 66.9% |
| EBITDA | $6,668 | $9,083 | $8,601 | $6,485 |
| % Margin | 21.3% | 29.9% | 29.3% | 26.3% |
| Net Income | $2,575 | $4,928 | $14,956 | $4,385 |
| % Margin | 8.2% | 16.2% | 51% | 17.8% |
| EPS Diluted | 1.24 | 2.4 | 2.4 | 2.7 |
| % Growth | -48.3% | 0% | -11.1% | – |
| Operating Cash Flow | $6,554 | $7,891 | $8,161 | $7,952 |
| Capital Expenditures | -$2,982 | -$1,633 | -$1,408 | -$2,654 |
| Free Cash Flow | $3,572 | $6,258 | $6,753 | $5,298 |